Optimisation of one-step desolvation and scale-up of gelatine nanoparticle production

References

• Ahlers M, Coester C, Zwiorek K, Zillies J. 2007. Nanoparticles and method for the production thereof. EP1793810 A1.
   Google Scholar
• Azarmi S, Huang Y, Chen H, Mcquarrie S, Abrams D, Roa W, Finlay WH, Miller GG, Lobenberg R. Optimisation of a two-step desolvation method for preparing gelatine nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharm Sci, 2006;9:124–32.
   PubMed Web of Science ®Google Scholar
• Babel W, Schulz D, Giesen-Wiese M, Seybold U, Gareis H, Dick E, Schrieber R, Schott A, Stein W. 2000. Gelatine. Ullmann's encyclopaedia of industrial chemistry. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.
   Google Scholar
• Ballantyne B, Jordan SL. Toxicological, medical and industrial hygiene aspects of glutaraldehyde with particular reference to its biocidal use in cold sterilisation procedures. J Appl Toxicol, 2001;21:131–51.
   PubMed Web of Science ®Google Scholar
• Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 2004;57:369–75.
   PubMed Web of Science ®Google Scholar
• Coester CJ, Langer K, Van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsul, 2000;17:187–93.
   PubMed Web of Science ®Google Scholar
• Devereux GS. Epidemiology, pathology, and pathophysiology. In: Currie G, Baker J, eds. Asthma. Oxford: Oxford University Press, 2012:1–13.
   Google Scholar
• Digenis GA, Gold TB, Shah VP. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci, 1994;83:915–21.
   PubMed Web of Science ®Google Scholar
• Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research. J Control Release, 2013;172:1075–91.
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm, 2005;298:315–22.
   PubMed Web of Science ®Google Scholar
• Fuchs S. 2010. Gelatine nanoparticles as a modern platform for drug delivery. Thesis, LMU Munich.
   Google Scholar
• Fuchs S, Klier J, May A, Winter G, Coester C, Gehlen H. Towards an inhalative in vivo application of immunomodulating gelatine nanoparticles in horse-related preformulation studies. J. Microencapsulation, 2012;29:615–25.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Kutscher M, Hertel T, Winter G, Pietzsch M, Coester C. Transglutaminase: New insights into gelatin nanoparticle cross-linking. J Microencapsul, 2010;27:747–54.
   PubMed Web of Science ®Google Scholar
• Gerrard JA, Brown PK, Fayle SE. Maillard crosslinking of food proteins I: The reaction of glutaraldehyde, formaldehyde and glyceraldehyde with ribonuclease. Food Chem, 2002;79:343–9.
   Web of Science ®Google Scholar
• Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine, 2012;7:2181–95.
   PubMed Web of Science ®Google Scholar
• Kari F. NTP technical report on the toxicity studies of Glutaraldehyde (CAS No. 111-30-8) adminstered by inhalation to F344/N rats and B6C3F1 mice. Toxicity Rep Ser, 1993;25:E1–E10.
   Google Scholar
• Kirschvink N, Reinhold P. Use of alternative animals as asthma models. Curr Drug Targets, 2008;9:470–84.
   PubMed Web of Science ®Google Scholar
• Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Gehlen H, Coester C. A nebulised gelatine nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses. Pharm Res, 2012;29:1650–7.
   PubMed Web of Science ®Google Scholar
• Klier J, Geis S, Steuer J, Reese S, Fuchs S, Mueller R, Winter G, Gehlen H. Comparison of nanoparticulate CpG immunotherapy with and without allergens in RAO‐affected horses. Equine Vet J, 2015a;47:26.
   PubMedGoogle Scholar
• Klier J, Lehmann B, Fuchs S, Reese S, Hirschmann A, Coester C, Winter G, Gehlen H. Nanoparticulate CpG immunotherapy in RAO-affected horses: Phase I and IIa study. J Vet Intern Med, 2015b;29:286–93.
   PubMed Web of Science ®Google Scholar
• Klier J, May A, Fuchs S, Schillinger U, Plank C, Winter G, Gehlen H, Coester C. Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatine nanoparticles. Vet Immunol Immunop, 2011;144:79–87.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov, 2006;5:471–84.
   PubMed Web of Science ®Google Scholar
• Léguillette R. Recurrent airway obstruction-heaves. Vet Clin North Am Equine Pract, 2003;19:63–86.
   PubMed Web of Science ®Google Scholar
• Marty J, Oppenheim R, Speiser P. Nanoparticles-a new colloidal drug delivery system. Pharmaceutica Acta Helvetiae, 1978;53:17.
   PubMedGoogle Scholar
• Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm, 2010;76:1–9.
   PubMed Web of Science ®Google Scholar
• Pali-Schöll I, Szöllösi H, Starkl P, Scheicher B, Stremnitzer C, Hofmeister A, Roth-Walter F, Lukschal A, Diesner SC, Zimmer A. Protamine-nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm, 2013;85:656–64.
   PubMed Web of Science ®Google Scholar
• Park KW. Protamine and protamine reactions. Int Anesthesiol Clin, 2004;42:135–45.
   PubMedGoogle Scholar
• Pirie RS. Recurrent airway obstruction: A review. Equine Vet J, 2014;46:276–88.
   PubMed Web of Science ®Google Scholar
• Prelaud AR, Fuchs S, Weber K, Winter G, Coester C, Mueller RS. In vitro effects of CpG oligodeoxynucleotides delivered by gelatine nanoparticles on canine peripheral blood mononuclear cells of atopic and healthy dogs: A pilot study. Vet Dermatol, 2013;24:494.
   PubMed Web of Science ®Google Scholar
• Schloegl W, Klein A, Fürst R, Leicht U, Volkmer E, Schieker M, Jus S, Guebitz GM, Stachel I, Meyer M, et al. Residual transglutaminase in collagen: Effects, detection, quantification, and removal. Eur J Pharma Biopharm, 2012;80:282–8.
   PubMed Web of Science ®Google Scholar
• Schultes S, Mathis K, Zillies J, Zwiorek K, Coester C, Winter G. Analysis of polymers and protein nanoparticles using asymmetrical flow field-flow fractionation (AF4). LCGC Europe, 2009;22:390–403.
   Web of Science ®Google Scholar
• Stradner A, Sedgwick H, Cardinaux F, Poon WCK, Egelhaaf SU, Schurtenberger P. Equilibrium cluster formation in concentrated protein solutions and colloids. Nature, 2004;432:492–5.
   PubMed Web of Science ®Google Scholar
• Sung HW, Liang IL, Chen CN, Huang RN, Liang HF. Stability of a biological tissue fixed with a naturally occurring crosslinking agent (genipin). J Biomed Mater Res, 2001;55:538–46.
   PubMed Web of Science ®Google Scholar
• Vivero‐Escoto JL, Slowing II, Trewyn BG, Lin VSY. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small, 2010;6:1952–67.
   PubMed Web of Science ®Google Scholar
• Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stockburger T, Marstaller T, Vogel V. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation. Int J Pharm, 2011;414:225–32.
   PubMed Web of Science ®Google Scholar
• Wagner I, Geh KJ, Hubert M, Winter G, Müller R. 2016. Manuscript in preparation.
   Google Scholar
• Wollensak G, Spoerl E. Collagen crosslinking of human and porcine sclera. J Cataract Refract Surg, 2004;30:689–95.
   PubMed Web of Science ®Google Scholar
• Won YW, Kim YH. Recombinant human gelatin nanoparticles as a protein drug carrier. J Control Release, 2008;127:154–61.
   PubMed Web of Science ®Google Scholar
• Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release, 2005;109:256–74.
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Li X, Lu CT, Xu YY, Lv HF, Dai DD, Zhang L, Sun CZ, Yang W, Li XK, et al. Experiment on the feasibility of using modified gelatine nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol, 2012;49:315–25.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Meng W, Li X, Gao H, Hanagata N. Design of mesoporous silica/cytosine − phosphodiester − guanine oligodeoxynucleotide complexes to enhance delivery efficiency. J Phys Chem C, 2011;115:447–52.
   Web of Science ®Google Scholar
• Zillies J. 2007. Gelatine Nanoparticles for Targeted Oligonucleotide Delivery to Kupffer Cells-Analytics, Formulation Development, Practical Application. Thesis, LMU Munich.
   Google Scholar
• Zillies JC, Zwiorek K, Hoffmann F, Vollmar A, Anchordoquy TJ, Winter G, Coester C. Formulation development of freeze-dried oligonucleotide-loaded gelatine nanoparticles. Eur J Pharm Biopharm, 2008;70:514–21.
   PubMed Web of Science ®Google Scholar
• Zwiorek K. 2006. Gelatine nanoparticles as delivery system for nucleotide-based drugs. Thesis, LMU Munich.
   Google Scholar
• Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C. Delivery by cationic gelatine nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res, 2008;25:551–62.
   PubMed Web of Science ®Google Scholar
• Zwiorek K, Kloeckner J, Wagner E, Coester C. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharm Sci, 2005;7:22–8.
   PubMedGoogle Scholar